Enfusion, Inc. (ENFN Quick QuoteENFN - Free Report) reported $49.46 million in revenue for the quarter ended June 2024, representing a year-over-year increase of 15.8%. EPS of $0.05 for the same period compares to $0.04 a year ago.

The reported revenue represents a surprise of -1.61% over the Zacks Consensus Estimate of $50.27 million. With the consensus EPS estimate being $0.06, the EPS surprise was -16.67%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Enfusion performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenues- Platform subscriptions

  : $45.79 million compared to the $46.68 million average estimate based on four analysts. The reported number represents a change of +15.6% year over year.

• Revenues- Managed services

  : $3.22 million versus the four-analyst average estimate of $3.38 million. The reported number represents a year-over-year change of +9.4%.

• Revenues- Other

  : $0.44 million versus $0.28 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +163.9% change.

View all Key Company Metrics for Enfusion here>>>

Shares of Enfusion have remained unchanged over the past month versus the Zacks S&P 500 composite's -6.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.